Connecting you to content on EBSCOhost

Works matching IS 13596535 AND DT 2023 AND VI 28 AND IP 5

Results: 5

1

Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach.

Published in:

Antiviral Therapy, 2023, v. 28, n. 5, p. 1, doi. 10.1177/13596535231199838

By:

Elkaeed, Eslam B.;
Alsfouk, Bshra A.;
Ibrahim, Tuqa H.;
Arafa, Reem K.;
Elkady, Hazem;
Ibrahim, Ibrahim M.;
Eissa, Ibrahim H.;
Metwaly, Ahmed M.

Publication type:

Article

2

Subacute thyroiditis following COVID-19 vaccination: Case presentation.

Published in:

Antiviral Therapy, 2023, v. 28, n. 5, p. 1, doi. 10.1177/13596535231208831

By:

Tomic, Aleksandra Z.;
Zafirovic, Sonja S.;
Gluvic, Zoran M.;
Samardzic, Vladimir S.;
Macvanin, Mirjana T.;
Radunovic, Maja L. J.;
Isenovic, Esma R.

Publication type:

Article

3

Andrographolide inhibits infectious bronchitis virus-induced apoptosis, pyroptosis, and inflammation.

Published in:

Antiviral Therapy, 2023, v. 28, n. 5, p. 1, doi. 10.1177/13596535231207499

By:

Jiachen Shen;
Qiuchi Xu;
Lu Chen;
Xinyu Chang;
Ruiting Shen;
Zhenhua Zhao;
Lifei Zhu;
Yifei Wu;
Xiaolin Hou

Publication type:

Article

4

HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective.

Published in:

Antiviral Therapy, 2023, v. 28, n. 5, p. 1, doi. 10.1177/13596535231201162

By:

Carr, Andrew;
Mackie, Nicola E.;
Paredes, Roger;
Ruxrungtham, Kiat

Publication type:

Article

5

Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation.

Published in:

Antiviral Therapy, 2023, v. 28, n. 5, p. 1, doi. 10.1177/13596535231195431

By:

Bassel, Marielle;
Romanus, Dorothy;
Tien Bo;
Sundberg, Aimee K.;
Okala, Sandra;
Hirji, Ishan

Publication type:

Article